Immunovant, Inc. (IMVT)
41.08
+0.77
(+1.91%)
USD |
NASDAQ |
Jul 09, 10:43
Immunovant Max Drawdown (5Y) : 93.59% for June 30, 2026
Max Drawdown (5Y) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| June 30, 2026 | 93.59% |
| May 31, 2026 | 93.59% |
| April 30, 2026 | 93.59% |
| March 31, 2026 | 93.59% |
| February 28, 2026 | 93.59% |
| January 31, 2026 | 93.59% |
| December 31, 2025 | 93.59% |
| November 30, 2025 | 93.59% |
| October 31, 2025 | 93.59% |
| September 30, 2025 | 93.59% |
| August 31, 2025 | 93.59% |
| July 31, 2025 | 93.59% |
| June 30, 2025 | 93.59% |
| May 31, 2025 | 93.59% |
| April 30, 2025 | 93.59% |
| March 31, 2025 | 93.59% |
| February 28, 2025 | 93.59% |
| January 31, 2025 | 93.59% |
| December 31, 2024 | 93.59% |
| November 30, 2024 | 93.59% |
| October 31, 2024 | 93.59% |
| September 30, 2024 | 93.59% |
| August 31, 2024 | 93.59% |
| July 31, 2024 | 93.59% |
| June 30, 2024 | 93.59% |
| Date | Value |
|---|---|
| May 31, 2024 | 93.59% |
| April 30, 2024 | 93.59% |
| March 31, 2024 | 93.59% |
| February 29, 2024 | 93.59% |
| January 31, 2024 | 93.59% |
| December 31, 2023 | 93.59% |
| November 30, 2023 | 93.59% |
| October 31, 2023 | 93.59% |
| September 30, 2023 | 93.59% |
| August 31, 2023 | 93.59% |
| July 31, 2023 | 93.59% |
| June 30, 2023 | 93.59% |
| May 31, 2023 | 93.59% |
| April 30, 2023 | 93.59% |
| March 31, 2023 | 93.59% |
| February 28, 2023 | 93.59% |
| January 31, 2023 | 93.59% |
| December 31, 2022 | 93.59% |
| November 30, 2022 | 93.59% |
| October 31, 2022 | 93.59% |
| September 30, 2022 | 93.59% |
| August 31, 2022 | 93.59% |
| July 31, 2022 | 93.59% |
| June 30, 2022 | 93.59% |
| May 31, 2022 | 93.13% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Summit Therapeutics, Inc. | 95.40% |
| Protagonist Therapeutics, Inc. | 85.79% |
| UroGen Pharma Ltd. | 92.16% |
| Cogent Biosciences, Inc. | 94.16% |
| Vaxcyte, Inc. | 76.22% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | 18.42 |
| Beta (5Y) | 0.7655 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 74.88% |
| Historical Sharpe Ratio (5Y) | 0.3463 |
| Historical Sortino (5Y) | 1.048 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 18.38% |